4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Telomir Pharmaceuticals, Inc. (TELO) operates in the Biotechnology industry and is headquartered in Miami, United States. Its market capitalization is roughly $87 million. In the fiscal year ended 2025-12-31, TELO reported $0M in revenue and ($10M) in net income.
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($10M) | ($12M) | ($4M) | ($1M) |
| Net Income | ($10M) | ($16M) | ($13M) | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($1M) | ($2M) | ($1M) | ($5M) | ($2M) | — |
| Net Income | ($1M) | ($2M) | ($1M) | ($5M) | ($2M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $7M | $1M | $5M | $0M | — |
| Total Liabilities | $1M | $1M | $1M | $1M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TELO viewer.
About TickerBase · Data methodology & sources